PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). Etoposide 115-124 AKT serine/threonine kinase 1 Homo sapiens 55-60 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). Etoposide 115-124 AKT serine/threonine kinase 1 Homo sapiens 68-77 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). Etoposide 115-124 AKT serine/threonine kinase 1 Homo sapiens 68-73 21730367-4 2011 MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking Akt-1(CA). Etoposide 115-124 AKT serine/threonine kinase 1 Homo sapiens 74-76 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Etoposide 58-67 AKT serine/threonine kinase 1 Homo sapiens 106-111 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Etoposide 58-67 AKT serine/threonine kinase 1 Homo sapiens 112-114 21730367-6 2011 Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Etoposide 58-67 AKT serine/threonine kinase 1 Homo sapiens 106-109 20338106-9 2010 Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC. Etoposide 243-252 AKT serine/threonine kinase 1 Homo sapiens 108-111 21325296-8 2011 A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment. Etoposide 202-211 AKT serine/threonine kinase 1 Homo sapiens 171-174 20369051-11 2010 CONCLUSION: Lung cancer cells lacking maspin could be resistant to chemotherapeutic drugs such as doxorubicin or etoposide, at least in part by maintaining Akt phosphorylation. Etoposide 113-122 AKT serine/threonine kinase 1 Homo sapiens 156-159 17935137-0 2008 Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Etoposide 113-122 AKT serine/threonine kinase 1 Homo sapiens 26-29 18695355-10 2008 In addition, constitutively active MEK and myristoylated-Akt adenovirus suppressed the cleavage of pro-caspase-9 and -3 and inhibited osteoclast apoptosis induced by etoposide. Etoposide 166-175 AKT serine/threonine kinase 1 Homo sapiens 57-60 19212674-3 2009 Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002. Etoposide 118-127 AKT serine/threonine kinase 1 Homo sapiens 9-12 19212674-3 2009 Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002. Etoposide 118-127 AKT serine/threonine kinase 1 Homo sapiens 153-156 19212674-3 2009 Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002. Etoposide 118-127 AKT serine/threonine kinase 1 Homo sapiens 153-156 17935137-4 2008 Etoposide and doxorubicin stimulated Akt and PI3K activities in 2 gastric cancer cell lines (BGC-823 and SGC-7901), and the activities were concentration and time-dependent. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 37-40 31554835-7 2019 Cisplatin and etoposide increased phosphorylation of AKT (S473) and GRK2 knockdown mitigated this increase. Etoposide 14-23 AKT serine/threonine kinase 1 Homo sapiens 53-56 16778834-2 2007 Previously, we found BDNF activation of TrkB through PI3K/Akt protects NB from etoposide/cisplatin-induced cell death. Etoposide 79-88 AKT serine/threonine kinase 1 Homo sapiens 58-61 16527552-0 2006 Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Etoposide 57-66 AKT serine/threonine kinase 1 Homo sapiens 14-17 16527552-9 2006 Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein. Etoposide 83-92 AKT serine/threonine kinase 1 Homo sapiens 16-19 16424010-6 2006 Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 32-35 16424010-6 2006 Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 176-179 16267399-6 2005 Etoposide activated NF-kB through PI3-kinase/Akt, and the transcription activation domain (TAD) of p65 was further activated by wild-type PDK-1. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 45-48 15703783-8 2005 An inducible activated form of Akt protects normal myeloid cells from Ara-C and etoposide-mediated apoptosis. Etoposide 80-89 AKT serine/threonine kinase 1 Homo sapiens 31-34 15287952-7 2004 When employed at 5 micromol/l, the Akt inhibitors markedly reduced the resistance of the leukaemic cell lines to etoposide or cytarabine. Etoposide 113-122 AKT serine/threonine kinase 1 Homo sapiens 35-38 12761490-4 2003 Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Etoposide 276-285 AKT serine/threonine kinase 1 Homo sapiens 132-135 12481412-13 2002 Expression of CA Akt by itself also induced resistance to etoposide-mediated apoptosis. Etoposide 58-67 AKT serine/threonine kinase 1 Homo sapiens 17-20 11864976-6 2002 Stably transfected L929 fibroblasts that overexpress Akt were resistant to etoposide and did not translocate Bax to the mitochondria or release cytochrome c. Etoposide 75-84 AKT serine/threonine kinase 1 Homo sapiens 53-56 11896462-8 2002 Finally, in Jurkat T cells stably expressing iAkt, CID-induced Akt activation rescued cells from apoptosis triggered by multiple apoptotic stimuli, including staurosporine, anti-Fas antibodies, PI3K inhibitors and the DNA damaging agent, etoposide. Etoposide 238-247 AKT serine/threonine kinase 1 Homo sapiens 46-49 17699715-0 2007 Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Etoposide 71-80 AKT serine/threonine kinase 1 Homo sapiens 34-37 17699715-3 2007 We identified that etoposide, a topoisomerase II inhibitor, caused selective killing of myristylated Akt (Akt-myr)-transduced Ink4a/Arf(-/-) astrocytes and U87MG cells in a dose- and time-dependent manner. Etoposide 19-28 AKT serine/threonine kinase 1 Homo sapiens 101-104 17699715-3 2007 We identified that etoposide, a topoisomerase II inhibitor, caused selective killing of myristylated Akt (Akt-myr)-transduced Ink4a/Arf(-/-) astrocytes and U87MG cells in a dose- and time-dependent manner. Etoposide 19-28 AKT serine/threonine kinase 1 Homo sapiens 106-113 17699715-4 2007 Etoposide-selective cytotoxicity in the Akt-myr-transduced cells was shown to be caused by nonapoptotic cell death and occurred in a p53-independent manner. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 40-43 17699715-5 2007 Etoposide caused severe reactive oxygen species (ROS) accumulation preferentially in the Akt-myr-transduced cells, and elevated ROS rendered these cells highly sensitive to cell death. Etoposide 0-9 AKT serine/threonine kinase 1 Homo sapiens 89-92 17699715-6 2007 The etoposide-selective cell death of Akt-myr-transduced cells was attenuated by pepstatin A, a lysosomal protease inhibitor. Etoposide 4-13 AKT serine/threonine kinase 1 Homo sapiens 38-41 17699715-7 2007 In the present study, we show that etoposide might possess a novel therapeutic activity for oncogenic Akt-transduced cancer cells to kill preferentially through ROS-mediated damage. Etoposide 35-44 AKT serine/threonine kinase 1 Homo sapiens 102-105 16427189-6 2006 Moreover, hypoxia activated the PI3K/Akt and ERK pathways, and blocking the activation of either pathway reversed resistance to UV- and etoposide-induced apoptosis in response to hypoxia. Etoposide 136-145 AKT serine/threonine kinase 1 Homo sapiens 37-40 16427189-7 2006 These results suggest that hypoxia confers resistance to UV- or etoposide-mediated apoptosis in lung cancer cells via the activations of the PI3K/Akt and the ERK pathways. Etoposide 64-73 AKT serine/threonine kinase 1 Homo sapiens 146-149 16721826-10 2006 The effects of etoposide and paclitaxel on Akt also differed between ASMCs and VSMCs. Etoposide 15-24 AKT serine/threonine kinase 1 Homo sapiens 43-46 15674326-0 2005 Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Etoposide 77-86 AKT serine/threonine kinase 1 Homo sapiens 99-102 15674326-6 2005 The G2/M arrest induced by etoposide was also enhanced or inhibited by expression of a constitutively activated or dominant-negative Akt mutant, respectively. Etoposide 27-36 AKT serine/threonine kinase 1 Homo sapiens 133-136 15674326-7 2005 Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide. Etoposide 143-152 AKT serine/threonine kinase 1 Homo sapiens 85-88 15674326-8 2005 These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2. Etoposide 60-69 AKT serine/threonine kinase 1 Homo sapiens 149-152 12970779-9 2003 Our findings demonstrate that, at a concentration which does not affect PI3K activity, the Akt inhibitor markedly reduced resistance of HL60AR cells to etoposide, cytarabine, TRAIL, ATRA, and ionizing radiation. Etoposide 152-161 AKT serine/threonine kinase 1 Homo sapiens 91-94 12869645-8 2003 The ability of aspirin to activate AKT protein was observed also in presence of etoposide cotreatment. Etoposide 80-89 AKT serine/threonine kinase 1 Homo sapiens 35-38 10669740-8 2000 Finally, Akt-transformed cells were shown to require NF-kappaB to suppress the ability of etoposide to induce apoptosis. Etoposide 90-99 AKT serine/threonine kinase 1 Homo sapiens 9-12 31885313-0 2020 Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway. Etoposide 11-28 AKT serine/threonine kinase 1 Homo sapiens 94-97 31885313-9 2020 Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator. Etoposide 42-59 AKT serine/threonine kinase 1 Homo sapiens 90-93 26046675-8 2015 Furthermore, transfection with constitutive active MKK1 or AKT vectors could rescue the XRCC1 protein level and also the cell survival suppressed by co-treatment with etoposide and resveratrol. Etoposide 167-176 AKT serine/threonine kinase 1 Homo sapiens 59-62 30121250-9 2018 In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc. Etoposide 220-229 AKT serine/threonine kinase 1 Homo sapiens 64-67 29309885-8 2018 Knockdown of HBXIP expression by RNAi abrogates the etoposide-activated ERK and Akt. Etoposide 52-61 AKT serine/threonine kinase 1 Homo sapiens 80-83 29953987-5 2018 We found that etoposide increased XPC expression in an AKT activation manner in 2 squamous cell carcinoma H1703 and H520 cells. Etoposide 14-23 AKT serine/threonine kinase 1 Homo sapiens 55-58 29953987-6 2018 Knockdown of XPC using siRNA or inactivation of AKT by pharmacological inhibitor PI3K inhibitor (LY294002) enhanced the cytotoxic effects of etoposide. Etoposide 141-150 AKT serine/threonine kinase 1 Homo sapiens 48-51 29953987-7 2018 In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide. Etoposide 148-157 AKT serine/threonine kinase 1 Homo sapiens 48-51 29953987-7 2018 In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide. Etoposide 148-157 AKT serine/threonine kinase 1 Homo sapiens 88-91 26046675-0 2015 Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells. Etoposide 21-30 AKT serine/threonine kinase 1 Homo sapiens 87-90 26046675-4 2015 However, the role of ERK1/2 and AKT-mediated XRCC1 expression in etoposide treatment alone or combined with resveratrol-induced cytotoxicity in NSCLC cells has not been identified. Etoposide 65-74 AKT serine/threonine kinase 1 Homo sapiens 32-35 26046675-5 2015 In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975. Etoposide 15-24 AKT serine/threonine kinase 1 Homo sapiens 87-90 26046675-6 2015 Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide. Etoposide 172-181 AKT serine/threonine kinase 1 Homo sapiens 95-98 26458825-0 2015 Akt is translocated to the mitochondria during etoposide-induced apoptosis of HeLa cells. Etoposide 47-56 AKT serine/threonine kinase 1 Homo sapiens 0-3 26458825-3 2015 During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis. Etoposide 7-16 AKT serine/threonine kinase 1 Homo sapiens 50-53 26458825-4 2015 However, the detailed mechanisms underlying Akt regulation in etoposide-mediated apoptosis remain to be determined. Etoposide 62-71 AKT serine/threonine kinase 1 Homo sapiens 44-47 26458825-5 2015 The present study investigated whether etoposide triggers the translocation of Akt into the mitochondria. Etoposide 39-48 AKT serine/threonine kinase 1 Homo sapiens 79-82 26458825-6 2015 It was found that Akt activity was increased and sustained during apoptosis triggered by etoposide in HeLa cells. Etoposide 89-98 AKT serine/threonine kinase 1 Homo sapiens 18-21 26458825-8 2015 Concomitantly, the depletion of Akt in the nuclear fraction was observed after etoposide treatment from analysis of confocal microscopy. Etoposide 79-88 AKT serine/threonine kinase 1 Homo sapiens 32-35 26458825-9 2015 The results suggest that etoposide-stimulated Akt is translocated into the mitochondria, thereby possibly enhancing its interaction with Smac and promoting apoptosis in HeLa cells. Etoposide 25-34 AKT serine/threonine kinase 1 Homo sapiens 46-49 25954860-7 2015 This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC. Etoposide 234-243 AKT serine/threonine kinase 1 Homo sapiens 146-149 26232556-0 2015 Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells. Etoposide 52-61 AKT serine/threonine kinase 1 Homo sapiens 100-103 24569089-8 2014 In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents. Etoposide 132-141 AKT serine/threonine kinase 1 Homo sapiens 86-89 25543088-4 2015 We found an inverse regulation of MYBBP1A and AKT phosphorylation (pAKT(Ser473)), which was characteristic for the pre-senescent state after etoposide administration in vitro. Etoposide 141-150 AKT serine/threonine kinase 1 Homo sapiens 46-49 24038446-0 2015 Phosphorylation of Smac by Akt promotes the caspase-3 activation during etoposide-induced apoptosis in HeLa cells. Etoposide 72-81 AKT serine/threonine kinase 1 Homo sapiens 27-30 24038446-3 2015 In this report, nevertheless, we focused our view on the novel role of Akt which involves in a pro-apoptotic action by phosphorylating second mitochondria derived activator of caspases (Smac) protein during etoposide-induced apoptotic processes. Etoposide 207-216 AKT serine/threonine kinase 1 Homo sapiens 71-74 24038446-7 2015 Taken together, we propose that the phosphorylation of Smac by Akt might be a novel mechanism that involves in amplification of caspase cascade pathway during etoposide-induced apoptosis in HeLa cells. Etoposide 159-168 AKT serine/threonine kinase 1 Homo sapiens 63-66 23579276-7 2013 In addition, etoposide activated p38 mitogen-activated protein kinase (MAPK), AKT and c-Jun N-terminal kinase. Etoposide 13-22 AKT serine/threonine kinase 1 Homo sapiens 78-81 24260231-7 2013 GSK3 inhibitors, including LiCl and SB216763, restored the sustained Chk1 activation and mitigated apoptosis in cells treated with etoposide and the inhibitors for aberrant kinases, PI3K, or Akt. Etoposide 131-140 AKT serine/threonine kinase 1 Homo sapiens 191-194 23796964-8 2013 Taken together, these results implicate the Akt/PTEN cellular axis as a major determinant of the etoposide resistance of HCC cells. Etoposide 97-106 AKT serine/threonine kinase 1 Homo sapiens 44-47 23796964-6 2013 We also establish that increased etoposide-induced multinucleation in HepG2 cells is dependent on the catalytic activity of Akt, as phosphatidylinositol-3-kinase inhibitors as well as the overexpression of kinase-defective Akt reversed this phenotype. Etoposide 33-42 AKT serine/threonine kinase 1 Homo sapiens 124-127 23796964-6 2013 We also establish that increased etoposide-induced multinucleation in HepG2 cells is dependent on the catalytic activity of Akt, as phosphatidylinositol-3-kinase inhibitors as well as the overexpression of kinase-defective Akt reversed this phenotype. Etoposide 33-42 AKT serine/threonine kinase 1 Homo sapiens 223-226 22488521-4 2013 On the other hand, these cells become sensitive to etoposide when Akt was inhibited. Etoposide 51-60 AKT serine/threonine kinase 1 Homo sapiens 66-69 21617849-0 2011 Aspirin reduces the apoptotic effect of etoposide via Akt activation and up-regulation of p21(cip). Etoposide 40-49 AKT serine/threonine kinase 1 Homo sapiens 54-57 23093908-0 2012 Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells. Etoposide 95-104 AKT serine/threonine kinase 1 Homo sapiens 66-69 23093908-5 2012 The phosphorylations of Akt and mitogen-activated protein kinases (MAPKs) in response to etoposide-induced DNA damage were analyzed by Western blotting. Etoposide 89-98 AKT serine/threonine kinase 1 Homo sapiens 24-27 23093908-10 2012 Overexpression of Bid suppressed the activation of Akt with respect to etoposide-induced DNA damage. Etoposide 71-80 AKT serine/threonine kinase 1 Homo sapiens 51-54 21784088-8 2011 Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt. Etoposide 121-130 AKT serine/threonine kinase 1 Homo sapiens 81-84 21784088-8 2011 Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt. Etoposide 121-130 AKT serine/threonine kinase 1 Homo sapiens 90-93 21784088-8 2011 Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt. Etoposide 121-130 AKT serine/threonine kinase 1 Homo sapiens 90-93 21784088-10 2011 These results suggest that inactivation of PTEN, which renders activation of Akt, may contribute largely for the etoposide-resistance character of Hep G2 cells. Etoposide 113-122 AKT serine/threonine kinase 1 Homo sapiens 77-80